Moroxite AB, a Swedish company specialized in innovative implants for spinal fusion, reports on positive outcome with complete spinal fusion for Xerafuse™ rhBMP-2 to replace autologous bone harvested from the patient’s iliac crest, and for  Xerafuse™ Tobramycin  as a bone graft extender to minimize post-operative infections.   The study was conducted by researchers at Lund University, Sweden, based on Moroxite AB ´s bone mineral platform using Xerafuse™ bi-phasic ceramic bea

MD PhD  Vetra Markevičiūtė , Department of Orthopedics and Traumatology, Lithuanian University of Health Sciences, Kaunas, has recently...

Dr. Xinggui Tian on June 24 2025 successfully defended his Ph.D. thesis “Advancing Spine Surgery with Innovative Applications of Calcium...

The synergistic integration of biologics and additive manufacturing (AM) technologies has catalyzed groundbreaking advancements in spinal...

We’re thrilled to announce that Moroxite AB has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...

The Board of Directors of Moroxite AB has appointed Fredrik Lindberg as the new CEO, and he will start May 5, 2025.  Fredrik Lindberg MD,...

Moroxite AB has successfully raised SEK 22 million— backed by current owners and a small number of selected new investors.   This funding...

Moroxite has successfully cleared Stage 1 of the EIC Accelerator programme for our innovative product, Xerafuse™. This bone mineral...

TERM group at LU presented their work at the recently held Orthopedic Research Society's Annual Meeting . Poster:  A Calcium...

Background On-site delivery of bioactive agents facilitates enhancing the effectiveness of spinal fusion. However, the FDA-approved...

Present key target in her role at Moroxite F is regulatory approval in US

Dr. Markevičiūtė has shown that CaS/HA augmentation combined with systemic bisphosphonate could be superior to present techniques

Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been FDA-approved for lumbar fusion, but supraphysiologic initial burst...

Fracture fixation in an ageing population is challenging and fixation failure increases mortality and societal costs. We report a novel...

A clinical feasibility study, conducted in collaboration with researchers from Sweden, Lithuania, Germany, and China, have yielded...

It is reassuring and gratifying for all of us at Moroxite F to have secured the funds to be able to continue working with strong progress

Moroxite F team comprising of CTO Deepak Raina and doctoral student Jintian Huang accompanied by Prof. Stefan Zwingenberger and his team...

Assistant Professor Erdem Aras Sezgin at Aksaray University of Medicine, Department of Orthopedics and Traumatology, Turkey has on...

Despite the glimmer of hope provided by the discovery and commercialization of bone morphogenetic protein-2 (BMP-2) as a bone graft...

We are delighted to introduce two talented professionals who have recently joined our team